Concepedia

Publication | Closed Access

Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997.

69

Citations

0

References

1997

Year

Janice P. Dutcher, Michael B. Atkins, Richard I. Fisher, Geoffrey R. Weiss, Kim Margolin, Frederick R. Aronson, Jeff Sosman, Michael T. Lotze, Michael Gordon, Theodore F. Logan,
PubMed

Abstract

Complete response rate and response duration appear to favor the high-dose intravenous rIL-2 regimen. This will require verification in a randomized study comparing the best high-dose arm (rIL-2 alone) with the best outpatient regimen (rIL-2/IFN-alpha). The Cytokine Working Group is currently conducting such a study.